Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-02 in Relapsed/Refractory B-cell Malignancies
NCT04933825Phase 1Unknown
- Sponsor
- EdiGene Inc.
- Start
- Jul 2021
- Primary completion
- Sep 2024
- Modality
- CRISPR-Cas9, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET-02 in B cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL), sponsored by EdiGene Inc. Primary endpoint: Incidence of adverse events at 2 years. Status: unknown.
02
Drugs
ET-02
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04933825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933825.